Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Monoclonal antibodies in cancer immunotherapy.

Literature DB >> 30311129

Monoclonal antibodies in cancer immunotherapy.

Ilgin Kimiz-Gebologlu¹, Sultan Gulce-Iz^1,2,3, Cigir Biray-Avci⁴.

Abstract

Nowadays, in cancer treatments, immunotherapy which can be classified as a cancer type specific therapy is more popular than non-specific therapy methods such as surgery, radiotherapy and chemotherapy. The main aim of immunotherapy is to enable patients' immune system to target cancer cells and destroy them. The mainly used treatment methods in cancer immunotherapy are cancer vaccines, adoptive cell therapy, cytokines and monoclonal antibodies. In this review, we discuss the immunotherapy approaches, especially monoclonal antibodies which are mostly used in cancer immunotherapy in clinical applications.

Entities: Disease Species

Keywords: Cancer; Immunotherapy; Monoclonal antibody; Treatment

Mesh：

Substances：

Year: 2018 PMID： 30311129 DOI： 10.1007/s11033-018-4427-x

Source DB: PubMed Journal: Mol Biol Rep ISSN： 0301-4851 Impact factor: 2.316

36 in total

1. Monoclonal antibodies in cancer therapy: 25 years of progress.

Authors: Robert K Oldham; Robert O Dillman
Journal: J Clin Oncol Date: 2008-04-10 Impact factor: 44.544

Review 2. Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear.

Authors: Peniel M Dimberu; Ralf M Leonhardt
Journal: Yale J Biol Med Date: 2011-12

Review 3. Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers.

Authors: A Krishnamurthy; A Jimeno
Journal: Drugs Today (Barc) Date: 2017-04 Impact factor: 2.245

4. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.

Authors: Benjamin Boyerinas; Caroline Jochems; Massimo Fantini; Christopher R Heery; James L Gulley; Kwong Yok Tsang; Jeffrey Schlom
Journal: Cancer Immunol Res Date: 2015-05-26 Impact factor: 11.151

Review 5. Mechanisms of action of therapeutic antibodies for cancer.

Authors: J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal: Mol Immunol Date: 2015-04-23 Impact factor: 4.407

Review 6. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.

Authors: Xuhui Zhou; Weiguo Hu; Xuebin Qin
Journal: Oncologist Date: 2008-09-08

Review 7. New approaches for cancer immunotherapy.

Authors: Ayfer Karlitepe; Ozgun Ozalp; Cigir Biray Avci
Journal: Tumour Biol Date: 2015-05-02

Review 8. Therapeutic monoclonal antibodies in oncology.

Authors: Adam P Levene; Guminder Singh; Carlo Palmieri
Journal: J R Soc Med Date: 2005-04 Impact factor: 18.000

Review 9. Cancer immunotherapy: the beginning of the end of cancer?

Authors: Sofia Farkona; Eleftherios P Diamandis; Ivan M Blasutig
Journal: BMC Med Date: 2016-05-05 Impact factor: 8.775

10. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.

Authors: Ju Yeon Lee; Hyun Tae Lee; Woori Shin; Jongseok Chae; Jaemo Choi; Sung Hyun Kim; Heejin Lim; Tae Won Heo; Kyeong Young Park; Yeon Ji Lee; Seong Eon Ryu; Ji Young Son; Jee Un Lee; Yong-Seok Heo
Journal: Nat Commun Date: 2016-10-31 Impact factor: 14.919

38 in total

Review 1. Epidrugs: targeting epigenetic marks in cancer treatment.

Authors: Cristiana Libardi Miranda Furtado; Maria Claudia Dos Santos Luciano; Renan Da Silva Santos; Gilvan Pessoa Furtado; Manoel Odorico Moraes; Claudia Pessoa
Journal: Epigenetics Date: 2019-07-13 Impact factor: 4.528

Review 2. Unraveling the regulatory role of endoplasmic-reticulum-associated degradation in tumor immunity.

Authors: Xiaodan Qin; William D Denton; Leah N Huiting; Kaylee S Smith; Hui Feng
Journal: Crit Rev Biochem Mol Biol Date: 2020-07-07 Impact factor: 8.250

3. Surface Glycoproteomic Analysis Reveals That Both Unique and Differential Expression of Surface Glycoproteins Determine the Cell Type.

Authors: Suttipong Suttapitugsakul; Lindsey D Ulmer; Chendi Jiang; Fangxu Sun; Ronghu Wu
Journal: Anal Chem Date: 2019-05-03 Impact factor: 6.986

4. Antibody Purification Using Affinity Chromatography.

Authors: Arabelle Cassedy; Richard O'Kennedy
Journal: Methods Mol Biol Date: 2022

Review 5. Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with ⁹⁰Y or ¹⁷⁷Lu.

Authors: Urszula Karczmarczyk; Agnieszka Sawicka; Piotr Garnuszek; Michał Maurin; Wioletta Wojdowska
Journal: J Med Chem Date: 2022-04-20 Impact factor: 8.039

Review 6. Small extracellular vesicles in cancer.

Authors: Komal Abhange; Amy Makler; Yi Wen; Natasha Ramnauth; Wenjun Mao; Waseem Asghar; Yuan Wan
Journal: Bioact Mater Date: 2021-04-07

Review 7. Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines.

Authors: Coral García-Fernández; Anna Saz; Cristina Fornaguera; Salvador Borrós
Journal: Cancer Gene Ther Date: 2021-04-09 Impact factor: 5.987

8. Synthetic Antibody Mimics Based on Cancer-Targeting Immunostimulatory Peptides.

Authors: Dante Descalzi-Montoya; Rachel A Montel; Keith Smith; Eugenia Dziopa; Andrieh Darwich; Zheng Yang; Constantine Bitsaktsis; Robert Korngold; David Sabatino
Journal: Chembiochem Date: 2020-11-02 Impact factor: 3.164

Review 9. Extracellular Vesicles and Their Current Role in Cancer Immunotherapy.

Authors: Carla Giacobino; Marta Canta; Cristina Fornaguera; Salvador Borrós; Valentina Cauda
Journal: Cancers (Basel) Date: 2021-05-10 Impact factor: 6.639

Review 10. The dark side of immunotherapy.

Authors: Nwanneka Okwundu; Douglas Grossman; Siwen Hu-Lieskovan; Kenneth F Grossmann; Umang Swami
Journal: Ann Transl Med Date: 2021-06